Hermansky-Pudlak Syndrome (HPS)
·MeSH: Hermanski-Pudlak Syndrome
Prevalence
30.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Preclinical(1)
Frequently asked questions
How many drugs are in development for Hermansky-Pudlak Syndrome (HPS)?
BioSniper tracks 1 drug in development for Hermansky-Pudlak Syndrome (HPS) across 1 company.
How many clinical trials target Hermansky-Pudlak Syndrome (HPS)?
There are 2 clinical trials targeting Hermansky-Pudlak Syndrome (HPS) tracked by BioSniper.
What is the prevalence of Hermansky-Pudlak Syndrome (HPS)?
The estimated prevalence of Hermansky-Pudlak Syndrome (HPS) is approximately 30.0 per 100,000 population.
Deep-dive into Hermansky-Pudlak Syndrome (HPS)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis